Recent Share Performance and Business Context

Rhythm Pharmaceuticals (RYTM) has drawn investor attention after recent share price moves, with the stock last closing at $96.79 and showing positive total returns over the past month and past 3 months.

The Boston based biopharmaceutical company focuses on rare neuroendocrine diseases, with revenue of $217.17 million and an annual revenue growth figure of 38.46%, alongside a reported net loss of $207.84 million.

Short term momentum in Rhythm Pharmaceuticals has been strong, with a 9.52% 7 day share price return and a 14.34% 90 day share price return, set against a year to date share price decline of 7.83% and a 1 year total shareholder return of 56.14%. This points to recent strength building on an already very strong multi year total shareholder return that is more than 5x over 3 years.

If you are interested in how other stocks with potential growth stories are trading, this is a good moment to scan the market for 38 healthcare AI stocks.

With Rhythm Pharmaceuticals combining rapid revenue growth, a sizeable reported net loss and a stock that has already delivered very strong multi year returns, investors now face a key question: is there still value on the table or is the market already pricing in future growth?

Most Popular Narrative: 30.6% Undervalued

Rhythm Pharmaceuticals' most followed valuation narrative puts fair value at $139.47 per share, well above the last close at $96.79. This is a sizeable gap for investors to unpack.

Upcoming potential regulatory approvals and launches for setmelanotide (IMCIVREE) in new indications like acquired hypothalamic obesity and Prader-Willi syndrome, alongside expansion into younger age groups, are set to materially grow Rhythm's commercial opportunity and topline over the next several years.

Read the complete narrative. Read the complete narrative.

Curious what is baked into that fair value number? The narrative leans on expectations for brisk revenue expansion, a sharp swing in profit margins and a future earnings multiple that stands well above current sector norms.

Result: Fair Value of $139.47 (UNDERVALUED)

However, Rhythm Pharmaceuticals still carries meaningful risks, including ongoing operating losses of $207.84 million and heavy reliance on setmelanotide as its primary value driver.

Another View on Rhythm Pharmaceuticals Valuation

The analyst narrative frames Rhythm Pharmaceuticals as 30.6% undervalued relative to a $139.47 fair value, yet the current P/S ratio of 30.5x tells a very different story. That compares with 10.8x for the wider US biotech group, 9.1x for close peers and a fair ratio of 20.1x, which implies a rich price tag and less room for error. So which signal should investors focus on when expectations are this high?

Next Steps

With sentiment around Rhythm Pharmaceuticals split between strong past returns and a premium P/S ratio, it helps to move quickly and test the numbers yourself. To see exactly what investors are optimistic about, review the company’s 3 key rewards

Looking for more investment ideas beyond Rhythm Pharmaceuticals?

Before moving on from Rhythm Pharmaceuticals, give yourself an edge by lining up a few fresh ideas that match different portfolio goals and risk levels.

• Target potential mispricing by scanning companies that combine quality fundamentals with attractive valuations through the 45 high quality undervalued stocks.
• Strengthen your income stream by focusing on resilient companies offering higher yields using the 8 dividend fortresses.
• Prioritise resilience by concentrating on companies with robust finances and consistent metrics through the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.